SCHEMBL4395964

SCHEMBL4395964

O=C(O)c1noc(-c2ccco2)c1Cc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
PTPN1 P18031 2/20 0.43
PKM P14618 1/20 0.43
HSD17B10 Q99714 4/20 0.42
RECQL P46063 2/20 0.42
POLB P06746 1/20 0.42
TSHR P16473 1/20 0.42
DAGLA Q9Y4D2 1/20 0.41
SCD O00767 2/20 0.40
SCD5 Q86SK9 2/20 0.40
ALOX15 P16050 2/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
CASP1 P29466 1/20 0.40
ESR2 Q92731 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4395634 0.83 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2NPC1RAB9APTPN1
SCHEMBL4395818 0.77 ALDH1A1 (0.50) ALDH1A1NPC1RAB9APTPN1PKM
SCHEMBL28061414 0.68 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2NPC1RAB9APKM
SCHEMBL23486577 0.68 GRIA1 (0.47) ALDH1A1PTPN1TSHRMEN1KMT2A
SCHEMBL768786 0.67 PTPN1 (0.63) ALDH1A1PTPN1HSD17B10IP6K1IP6K3
SCHEMBL13319945 0.65 PKM (0.41) ALDH1A1PKM
SCHEMBL22609285 0.65 SRD5A2 (0.51) ALDH1A1TSHRMEN1KMT2A
SCHEMBL21313185 0.65 ADORA2A (0.59)
SCHEMBL21523611 0.64 KDM4E (0.56) ALDH1A1SMN1; SMN2NPC1RAB9APKM
SCHEMBL1226204 0.64 PTPN1 (0.58) ALDH1A1SMN1; SMN2NPC1RAB9APTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP claimed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US claimed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP claimed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO claimed
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 ALDH1A1 706/4885SMN1; SMN2 3980/4885NPC1 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.